Australia Medical Devices Market Report 2026: TGA Registration, Prostheses List, and MSAC Reimbursement Intelligence

The Australian medical devices market is estimated at USD 9–11 billion in 2026, growing at approximately 5.5% CAGR. Australia is a significant medical device market driven by its Medicare-funded universal healthcare system, high private health insurance coverage (45% of population), and a premium private hospital sector. The Therapeutic Goods Administration (TGA) regulates device registration through the ARTG (Australian Register of Therapeutic Goods), and Australia participates in the Access Consortium enabling recognition of regulatory decisions from MHRA, Health Canada, HSA Singapore, and Swissmedic.

The TGA registers medical devices on the ARTG (Australian Register of Therapeutic Goods) under a risk classification system: Class I (lowest risk — self-certification); Class IIa, IIb (moderate-high risk — conformity assessment required); Class III and Active Implantable Medical Devices (highest risk — TGA clinical evidence review required). CE marking (EU MDR) and FDA clearance/approval are accepted as supporting evidence under TGA's international recognition procedures, though TGA conducts its own assessment. TGA participates in the IMDRF and has adopted the Medical Device Single Audit Program (MDSAP). The TGA also oversees the Australian Adverse Event Management System (AIMS) for post-market vigilance.

Medical device reimbursement in Australia operates through two main channels: (1) MBS (Medicare Benefits Schedule) — procedure-based reimbursement for outpatient and day procedure services that include device use. MSAC (Medical Services Advisory Committee) assesses new medical services and technologies for MBS listing through the Health Technology Assessment process; (2) Prostheses List — for private health insurance-covered devices used in hospital procedures. The Prostheses List includes over 10,000 implantable devices (cardiac devices, orthopaedic implants, cochlear implants, etc.) with listed benefits that private health insurers must pay for insured patients. The Prostheses List is administered by the Department of Health and has been subject to price reform programs reducing manufacturer prices.

The five largest Australian medical device segments by value are: cardiovascular devices (cardiac rhythm management, coronary stents, TAVR — Australia has a large cardiovascular disease burden; Prostheses List drives high-volume cardiac device procurement); orthopaedics and joint replacement (Australia has among the highest joint replacement rates per capita in the world; Prostheses List covers hip and knee implants); in vitro diagnostics (pathology diagnostics — Australia has an extensive pathology network; Sonic Healthcare, Healius, Australian Clinical Labs); diagnostic imaging (MRI, CT, nuclear medicine — Australia has high imaging utilisation, especially in the private sector); and cochlear implants (Cochlear Limited, headquartered in Sydney, is the world's leading cochlear implant manufacturer).

Australia's Prostheses List is the primary reimbursement mechanism for medical devices used in privately insured patients. The government has pursued Prostheses List price reform since 2018, seeking to reduce device costs and PHI premiums — achieving significant price reductions for orthopaedic implants (average 40–50% cuts for hip and knee components), cardiac devices, and other categories. The reforms have created commercial pressure for both international and domestic device manufacturers. Simultaneously, Prostheses List listing remains essential for access to Australia's large private hospital sector — over 600 private hospitals treating approximately 40% of all Australian hospital procedures.

Before a device can be legally supplied in Australia, its sponsor — a locally based entity accepting regulatory responsibility, as overseas manufacturers cannot apply directly — must secure inclusion on the ARTG (Australian Register of Therapeutic Goods). Class I devices without a measuring function typically self-certify via a Declaration of Conformity, while Class IIa, IIb, III, and Active Implantable Medical Devices require a Conformity Assessment Certificate demonstrating compliance with the Essential Principles for safety and performance. TGA's standard evaluation runs approximately 12 months, but the Access Consortium reliance pathway — recognising recent approvals from the MHRA, Health Canada, HSA Singapore, or Swissmedic — can compress review to as little as two months for eligible applications. TGA also participates in the Medical Device Single Audit Program (MDSAP), allowing a single quality management system audit to satisfy multiple regulators simultaneously. Sponsors must maintain post-market vigilance obligations, including mandatory adverse event reporting through the TGA's device incident reporting system, once ARTG inclusion is granted.

MSAC (Medical Services Advisory Committee) is the independent body that evaluates the comparative safety, clinical effectiveness, and cost-effectiveness of new medical technologies and procedures proposed for public funding through the Medicare Benefits Schedule, operating separately from — and after — TGA's ARTG registration decision. The MSAC pathway begins with a PICO Confirmation (Population, Intervention, Comparator, Outcome) that defines the clinical question, followed by an evidence-based assessment report, public consultation, and a committee recommendation to government, typically spanning 12–24 months end to end. For implantable devices funded through private health insurance rather than Medicare, a related but distinct process run by the Prostheses List Advisory Committee (PLAC) governs Prostheses List inclusion and benefit-setting. Device sponsors frequently need to navigate both TGA registration and the relevant HTA pathway (MSAC or PLAC) in parallel to secure full commercial market access. BioNixus tracks MSAC and PLAC submission outcomes to help device manufacturers anticipate reimbursement timelines ahead of launch.

BioNixus delivers medical device market research in Australia: regulator-aware access intelligence, hospital consumption analogues, physician and payer qualitative programmes, and launch evidence under EphMRA and BHBIA governance with GDPR-aligned fieldwork for multinational sponsors. Teams receive decision-ready outputs validated against national policy and institution-level adoption—not desk extrapolation from unrelated regions.

BioNixus supports Australia-based medical device companies expanding into GCC and MENA markets with SFDA and MOHAP regulatory intelligence, NUPCO and hospital procurement tracking in Saudi Arabia, UAE insurer and formulary research, physician panels across GCC countries, and comparative Australia versus GCC market intelligence. GCC expansion is a distinct service line with its own tender and access calendars—see our GCC pharmaceutical market report for regional context. Launch assumptions should be validated market by market rather than from a single Gulf average.